Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

BREAKING NEWS

Biogen Idec selects Quintiles in 5-year strategic partnership

Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.

Related news

News in brief

SAS, a provider of tools for data and health analysis, will supply the platform for a project sharing oncology data from studies by AstraZeneca, Janssen R&D, Pfizer and Sanofi.

A new report says the Japanese CRO market is seeing more growth as Japanese pharma firms, which traditionally kept research in-house, are now broadening their horizons to use more outsourcing partners.

CROs could benefit from a €3bn ($4.1bn) research programme run jointly by the European Commission and the pharmaceutical industry, according to ACRO.

Our round-up of who to watch this week in contract pharma starts with executive changes at PPD.

Global Industry News

Opko acquires Israeli-made dry powder inhaler to treat respiratory disorders from in-PharmaTechnologist.com

Opko Health has agreed to acquire Inspiro Medical, an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. 

Generation of biobetters could push out biosimilar development, says expert from BioPharma-Reporter.com

The latest generation of “biobetters” which are engineered to be more effective than branded biologics are hitting the market before biosimilars and could make development of the latter pointless, an expert has said.

UK generics makers and MHRA pool manufacturing knowledge from in-PharmaTechnologist.com

The British Generic Manufacturers Association (BGMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) will launch a forum for the generics industry to discuss manufacturing and quality issues.

Frutarom becomes a bigger botanicals player with THMPD range from NutraIngredients.com

Swiss-Israeli supplier Frutarom has beefed up its botanical extracts in response to changing European Union laws for herbal products and medicines.

US FDA offers guidance on when two mAbs should be considered the same from BioPharma-Reporter.com

As the race to develop mAbs (monocolonal antibodies) heats up and companies vie for the elusive seven years exclusivity that comes with an orphan drug designation, the US FDA is now offering guidance on when two mAbs should be viewed as the same.

Novartis scoops GSK’s oncology portfolio, trades away its vaccine division from in-PharmaTechnologist.com

Novartis has agreed to acquire GlaxoSmithKline’s oncology pipeline for as much as $16bn, while GSK will acquire Novartis’ vaccine business, excluding the flu vaccines, for as much as $7bn.

FDA ‘breakthrough’ scheme approves GSK biologic, but is it faster? from BioPharma-Reporter.com

The US Food and Drug Administration (FDA) has approved a second “Breakthrough Therapy” biologic but it is still unclear whether the programme speeds drugs to market, says an expert.

Spotlight

CROs to 'push' patients into trials using partners, report predicts

CROs to 'push' patients into trials using partners, report predicts

Patient recruitment is “the major bottleneck” in clinical development, an Industry Standard Research report says, but though it predicts...

EU law: public database for trial transparency

EU law: public database for trial transparency

Companies running clinical trials will have to use an online portal to stay on the right side...

Always on my mind or return to vendor? CRO models discussed in Vegas

Always on my mind or return to vendor? CRO models discussed in Vegas

Big Pharma's split opinion on the best way to work with a CRO was in evidence in...

Quality and IP issues driving sponsors away from Indian CMOs, experts say

Quality and IP issues driving sponsors away from Indian CMOs, experts say

Quality and IP issues are driving firms back to the US and Europe for their contract manufacturing...

CROs debate: Can surrogate endpoints speed oncology drugs to market?

CROs debate: Can surrogate endpoints speed oncology drugs to market?

As biopharma companies look to develop cancer therapies more quickly, some are turning to CROs with the...

Consolidation prevalent in industry, says third largest CMO
Dispatches from interphex

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Key Industry Events

 

Access all events listing

Our events, Events from partners...